An expanded ACTIV-6 study will test 600 mcg/kg of ivermectin daily for six days in patients who have had a positive COVID-19 test within the past 10 days, and have at least two symptoms of the illness for no more than seven days.
Novavax Inc has received authorizations for its COVID-19 vaccine NVX-CoV2373 (brand name Nuvaxovid) in Great Britain and in New Zealand, the company reports.
The French pharmaceutical company Valneva announced positive topline results from the Phase 3 trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
New data released by AstraZeneca Thursday report its vaccine was 76% effective at overall prevention of symptomatic COVID-19, 85% effective in adults 65 and older, and 100% effective in preventing severe or critical disease and hospitalization.
Read More
A Data & Safety Monitoring Board expressed concern that AstraZeneca may have included outdated information in a Phase 3 trial for its COVID-19 vaccine.
Read More
AstraZeneca says it will submit its COVID-19 vaccination for FDA authorization after phase 3 trial results found the vaccine to be 79% effective at preventing symptomatic COVID-19 and 100% effective at preventing severe disease and hospitalization.
Read More
AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorization in the European Union for adults 18 and older.
Read More
The vaccine candidate had an 85% overall efficacy at preventing severe disease 28 days after vaccination and a 66% overall efficacy rate in preventing moderate-to-severe COVID-19.
Read More
Pharmaceutical company Novartis will assist Pfizer and BioNTech in the production of their COVID-19 vaccine.
Read More
Novavax Inc’s COVID-19 vaccine candidate had a vaccine efficacy of 89.3% in a Phase 3 UK clinical trial, but appeared less effective (60%) against a South Africa variant.
Read More
The antibodies from people who have received the Pfizer BioNTech COVID-19 vaccine effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains.
Read More
COVID-19 patients in the United Kingdom are now able to be treated with tocilizumab and sarilumab — drugs used to treat rheumatoid arthritis that recent studies showed can significantly reduce mortality risk and length of hospital stay up to 10 days.
Read More
Healthcare officials are weighing whether to delay the second doses of the COVID-19 vaccine or to halve the recommended dose in order to reach more people.
Read More
Carrimycin has become the world’s first synthetic biological drug treatment for severe COVID-19 to receive US FDA approval for Phase III trials, according to its developer, the Tonglian Group.
Read More
Valneva SE, has initiated a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Read More